NOTE 4 – SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION
Revenue:
| |
|
|
|
|
Three months ended
June 30
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Royalties revenue
|
|
$
|
1,056
|
|
|
$
|
683
|
|
|
$
|
612
|
|
|
$
|
530
|
|
|
Sale of IP
|
|
|
4,800
|
|
|
|
16,000
|
|
|
|
4,800
|
|
|
|
16,000
|
|
|
License revenue
|
|
|
- |
|
|
|
1,577
|
|
|
|
- |
|
|
|
717
|
|
|
Support services
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
5,899
|
|
|
$
|
18,292
|
|
|
$
|
5,433
|
|
|
$
|
17,261
|
|
Research and development expenses:
| |
|
|
|
|
Three months ended
June 30
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
Payroll and related expenses
|
|
$
|
1,957
|
|
|
|
1,687
|
|
|
$
|
1,000
|
|
|
$
|
763
|
|
|
Clinical and preclinical trials expenses
|
|
|
3,693
|
|
|
|
3,660
|
|
|
|
905
|
|
|
|
1,850
|
|
|
Professional consulting and subcontracted work
|
|
|
1,451
|
|
|
|
4,722
|
|
|
|
214
|
|
|
|
1,656
|
|
|
Supplier-led manufacturing development
|
|
|
-
|
|
|
|
2,749
|
|
|
|
-
|
|
|
|
-
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Research and development expenses
|
|
$
|
7,783
|
|
|
$
|
13,489
|
|
|
$
|
2,438
|
|
|
$
|
4,646
|
|
|